Canaccord noted Akero reported top-line results from the Phase IIb SYMMETRY trial for efruxifermin (EFX) in F4 NASH cirrhotic patients. The study missed its primary endpoint of greater than or equal to1-stage fibrosis improvement. The firm believes the reaction is extreme and shares are oversold. Canaccord remaind bullish on shares of Aero and reiterates its Buy rating and $59 price target on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKRO:
- Morgan Stanley removes Akero as Top Pick, cuts target to $33
- 89bio downgraded to Perform at Oppenheimer on reduced FGF21 confidence
- 89bio price target lowered to $27 from $34 at RBC Capital
- 89bio down 27% after Akero reports NASH trial data
- Akero Therapeutics reports 36-week analysis of Phase 2b SYMMETRY study